ArticleDialogues in clinical neuroscience2009
Major depression during interferon-alpha treatment: vulnerability and prevention.
Article in Dialogues in clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 59 citations in OpenAlex.
- Trial
- Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.Psychological medicine · 2012Trial
- Kynurenine pathway dysregulation in major depressive disorder: the convergence of excitotoxicity, neuroinflammation, and oxidative stress.Journal of neuroinflammation · 2026Review
- Comprehensive view of suicide: A neuro-immune-endocrine approach.World journal of psychiatry · 2025Review
- Virus-host interaction mechanisms in interferon therapy for hepatitis B virus infection: recent advances.Frontiers in immunology · 2025Review
- Neurodevelopmental and Neuropsychiatric Disorders.Advances in neurobiology · 2024Review
- Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer's Disease and Geriatric Depression.Brain sciences · 2023Review
- Effects of Ozone on Sickness and Depressive-like Behavioral and Biochemical Phenotypes and Their Regulation by Serum Amyloid A in Mice.International journal of molecular sciences · 2023Article
- Blockade of kappa-opioid receptors amplifies microglia-mediated inflammatory responses.Pharmacology, biochemistry, and behavior · 2022Article
- The Pharmacologically Active Alkaloid Cryptolepine Activates a Type 1 Interferon Response That Is Independent of MAVS and STING Pathways.Journal of immunology research · 2022Article
- Lower Levels of GABAergic Function Markers in Corticotropin-Releasing Hormone-Expressing Neurons in the sgACC of Human Subjects With Depression.Frontiers in psychiatry · 2022Article
- Choroid plexus enlargement is associated with neuroinflammation and reduction of blood brain barrier permeability in depression.NeuroImage. Clinical · 2022Article
- Host Manipulation Mechanisms of SARS-CoV-2.Acta biotheoretica · 2021Article
- Peripheral Markers of Depression.Journal of clinical medicine · 2020Review
- The pandemic exposes human nature: 10 evolutionary insights.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management.Therapeutic advances in musculoskeletal disease · 2020Review
- The effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder: A randomized clinical trial.Electronic physician · 2017Article
- Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Review
- Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.Psychopharmacology · 2016Article
- Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.Brain : a journal of neurology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Major Depressive Disorder (MDD) during interferon-alpha (IFN-alpha) treatment can occur within a few months of therapy, and shares many homologies with other forms of MDD. Most patients are resilient to the side effect of interferon-induced depression (IFN-MDD), but 15% to 40% are vulnerable. Several studies have employed antidepressants to prevent the incidence of an IFN-MDD episode, and the results suggest that prophylactic antidepressants may be specifically useful in those with pre-existing subthreshold depressive symptoms and/or a history of prior MDD episodes. Several other potential markers of vulnerability for IFN-MDD have been implicated in assessments of nondepressed patients before they start IFN-alpha. These include poor sleep quality, premorbid elevations in inflammatory cytokines, genetic polymorphisms in the serotonin system, personality, and social support. The interplay of these factors strongly predicts who is at risk for IFN-MDD, and indicates several potentially modifiable targets for the personalized prevention of IFN-MDD.
Indexed as
Identifiers
20135899PMC3181938W139062450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.